May 16, 2021 7:58 pm Published by admin SAN DIEGO, Nov. 11, 2020 /PRNewswire/ —InhibRx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, announced updated interim results today from a Phase 1 clinical trial evaluating the efficacy and safety of INBRX-109 in patients with chondrosarcoma. This data will be presented to attendees of the Annual Connective Tissue Oncology Society [...]
May 8, 2021 7:58 pm Published by admin This coming Friday will be the Chondrosarcoma Foundation’s first anniversary. Last year, on May 14, 2020 during the beginning of the pandemic, we launched the Chondrosarcoma Foundation by bringing CS Foundation web site on-line. My daughter Shayna Elise Kramer expressed a desire to educate the world about Chondrosarcoma so she could help others suffering from [...]
May 7, 2021 10:28 pm Published by admin November 13, 2020 Dylann Cohn-Emery Treatment with the investigation agent INBRX-109 induced responses and decreased the tumor burden in a cohort of patients with chondrosarcoma, according to interim efficacy and safety findings a phase 1 trial in patients with chondrosarcoma, Inhibrx, Inc announced in a press release. Treatment with the investigation agent INBRX-109 induced responses [...]
May 7, 2021 10:28 pm Published by admin Inhibrx Granted Fast Track Designation for INBRX-109 for the Treatment of Unresectable or Metastatic Conventional Chondrosarcoma Patients Registration-enabling study expected to begin dosing in the second or third quarter of this year
April 30, 2021 5:48 pm Published by admin Elena Cojocaru, Christopher Wilding, Bodil Engelman, Paul Huang & Robin L. Jones Current Molecular Biology Reports volume 6, pages1–9(2020)Cite this article Is the IDH Mutation a Good Target for Chondrosarcoma Treatment? | SpringerLink detail Abstract Chondrosarcomas are rare cancers of bone that arise from the malignant transformation of cells of chondrocytic lineage. They are known [...]
April 30, 2021 4:41 pm Published by admin Abstract Dioxins are ubiquitous and persistent environmental contaminants whose background levels are still reason for concern. There is mounting evidence from both epidemiological and experimental studies that paternal exposure to the most potent congener of dioxins, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), can lower the male/female ratio of offspring. Moreover, in laboratory rodents and zebrafish, TCDD exposure of parent [...]
April 30, 2021 2:41 pm Published by admin Sebastien passed away July 14, 2020 from dedifferentiated chondrosarcoma. This narrative was written and submitted by his sister Stephanie Desjardins. In April 2019, my brother was diagnosed with a chondrosarcoma of chest wall on the right side with, what we were going to learn later was he had two metastases on his lung. He was [...]
April 29, 2021 3:38 pm Published by admin Empowering Patients: Speak Up For Your Health Tuesday, May 11, 2021 at 12:00 PM ET Please consider registering to a special information session where our panel of experts will discuss the importance of advocating for patient care and treatment. They will address your specific questions and concerns and share tools and knowledge that will give [...]
April 24, 2021 3:19 pm Published by admin The Bone Cancer Research Trust is hosting a free Support & Information Webinar. It features Carol Hughes who will provide a presentation on Managing the fear of recurrence, On Thursday 29th April We know that when treatment for primary bone cancer finishes, feelings of anxiety do not suddenly end but take on a different meaning [...]
April 23, 2021 4:32 am Published by admin Proton therapy induces biologic response to attack treatment-resistant cancers February 17, 2021 ROCHESTER, Minn. — Mayo Clinic researchers have developed a novel proton therapy technique to more specifically target cancer cells that resist other forms of treatment. The technique is called LEAP, an acronym for “biologically enhanced particle therapy.” The findings are published today in [...]
